Autolus Therapeutics plc

Healthcare · Biotechnology · United Kingdom

Last price 1.52 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 404.57M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in ph...